Last update 01 Nov 2024

Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.

Private Company|
2018|
Shanghai Shi, China
|
www.dashengpharma.com

Overview

Tags

Immune System Diseases
Hemic and Lymphatic Diseases
Neoplasms
Autologous CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Immune System Diseases1
Neoplasms1
Top 5 Drug TypeCount
Autologous CAR-T1
Top 5 TargetCount
CD19(B-lymphocyte antigen CD19)1

Related

1
Drugs associated with Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.
HR-001
Target
CD19
Mechanism
CD19 modulators [+1]
Active Org.
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.Startup [+1]
Originator Org.
Hrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.Startup
Active Indication
B-cell lymphoma recurrent [+2]
Inactive Indication
CD19 positive Acute Lymphoblastic Leukemia [+6]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Hengrun Dasheng Biopharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
HR-001
 ( CD19 )		B-cell lymphoma refractory
More
NDA/BLA
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free